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DEPARTMENT OF HEALTH AND HUMAN SERVICES 
CENTERS FOR DISEASE CONTROL AND PREVENTION 
National Center for HIV/AIDS, Vital Hepatitis, STD and TB Elimination 
Division of Tuberculosis Elimination 
Advisory Council for the Elimination of Tuberculosis 
June 5, 2012 
Atlanta, GA and via teleconference 
Minutes of the Meeting 
The Department of Health and Human Services (HHS) Centers for Disease Control and 
Prevention (CDC), National Center for HIV/AIDS, Viral Hepatitis, STD and TB Elimination 
(NCHHSTP) Division of Tuberculosis Elimination (DTBE) convened a meeting of the Advisory 
Council for the Elimination of Tuberculosis (ACET) on June 5, 2012, via teleconference and in 
person in Building 8 of CDC’s Corporate Square Campus, Conference Room A/B/C, in Atlanta, 
Georgia. 
Call to Order, Welcome, and Roll Call:  June 5, 2012 
Shannon Jones III 
Acting Director of Public Health and Community Services, 
City of Austin / Travis County 
Texas Health and Human Services Department 
ACET Chair 
Mr. Jones called the meeting of ACET to order at 11:02 a.m. on Tuesday, June 5, 2012.  He 
noted that the Webinar format was new for ACET and that they would conduct at least one 
meeting per year via Webinar.  He asked meeting participants to share their feedback regarding 
the format.  He emphasized the importance of maintaining a quorum throughout the meeting. 
Hazel Dean, ScD, MPH 
Deputy Director, NCHHSTP 
Centers for Disease Control and Prevention 
ACET Designated Federal Official 
Dr. Dean reminded the group that all ACET meetings are open to the public, and all comments 
made during the meeting are a matter of public record.  Members should be mindful of potential 
conflicts of interest (COI) identified by CDC’s Committee Management Office (CMO) and should 
recuse themselves from voting or participating in those discussions.  She asked that ACET 
members identify potential conflicts of interest during the roll call. 
Dr. Dean recognized that ACET members Dr. Iram Bakhtawar and Dr. Christine Hahn would 
rotate off of the committee as of June 30, 2012.  She thanked them for their contributions and 
said that a Certificate of Appreciation signed by CDC Director Dr. Tom Frieden and NCHHSTP 
Director Dr. Kevin Fenton would be mailed to them.  Approval has been received for a 
nomination package for members to replace Drs. Bakhtawar and Hahn.  Dr. Dean welcomed ex 
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officio members Dr. J. Nadine Gracia from the Office of Minority Health (OMH) and Dr. Craig 
Shapiro from the Office of Global Affairs (OGA). 
Dr. Dean conducted a roll call of ACET voting members, ex officio members, and liaison 
representatives who were present in person and via teleconference.  She verified a quorum of 
ACET voting members and ex officio members. 
Mr. Robert Scott, CDC, oriented ACET regarding protocols and procedures for participating in 
the meeting. 
Modeling TB Epidemiology 
Andrew Hill, PhD 
Data Management and Statistics Branch 
Division of Tuberculosis Elimination/NCHHSTP 
Centers for Disease Control and Prevention 
Dr. Hill presented a recently-published transmission model for tuberculosis (TB) trends in the 
United States (US) and discussed projections of TB trends for the US-born and foreign-born 
populations. 
The TB elimination goal is 1 case per million annually.  In 1989, the ACET Strategic Plan set 
strategic goals for elimination by 2010, with an interim goal of 35 cases per million by 2000.  
CDC surveillance indicates that overall incidence rates in 2000 were 58 cases per million, and in 
2010 were 36 cases per million.  If current rates of decline are maintained, then elimination of 
TB throughout the US could be expected by the early 22nd Century. 
In 2010, 60% of all TB cases were among the foreign-born population.  The foreign-born 
population itself constituted 12% of the total US population.  At that time, the US-born 
population experienced TB rates of 16 cases per million, and the foreign-born population TB 
rate was 181 per million.  If current rates of decline persist, then elimination of TB is expected in 
the US-born population by the middle of the 21st Century, and in the foreign-born population by 
the middle of the 22nd Century. 
Dr. Hill shared with ACET a graphic representation of TB incidence trends in the US from 1993 
through 2010.  Until the year 2000, TB incidence in the overall US population was declining at a 
rate of 7.3% per year.  The rate of decline then slowed to 3.8%.  TB rates in the foreign-born 
population have declined at a steady rate of 3.8% per year.  TB rates in the US-born population 
also declined in 2002 from a rate of 10% per year to a rate of 5.9% per year.  Because of an 
unexpected decrease in cases, the rates have not been extrapolated beyond the year 2008; 
however, Dr. Hill provided data points for 2009 and 2010 for reference.  The number of TB 
cases in the foreign-born population has remained relatively constant in recent years, but the 
contribution of cases from the foreign-born population has increased. 
Reactivated TB plays a significant role in driving TB incidence in the US.  The World Health 
Organization (WHO) estimate for worldwide latent TB infection (LTBI) is approximately one-third 
of the world population.  A probable estimate of LTBI that is imported into the US among newly-
arriving foreign-born persons is approximately 20%.  A National Health and Nutrition 
Examination Survey (NHANES) study in 2000 estimated LTBI prevalence in the overall US 
population at 4.2%, or 11 million people.  LTBI prevalence in the US-born population was 1.8%, 
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or 5 million people, and 18.7%, or 6 million people, in the foreign-born population.  Genotyping 
studies have indicated that the proportion of cases due to reactivation, as opposed to recent 
infection, is approximately 60% to 70% in the US-born population and 75% to 85% in the 
foreign-born population.  These data informed the TB transmission model. 
The scope of the TB transmission model was to develop a relatively simple model based on 
previously-published paradigms and TB transmission models in the literature to assess relative 
impacts on time to elimination of treatment of active TB disease and LTBI.  The model aimed to 
assess whether the constant rates of decline will persist.  The model also incorporated the 
contributions of incidence rate in the foreign-born population to overall incidence rates.  Finally, 
the model assessed the effect of reducing transmission of disease as an interim step to 
elimination. 
The model structure is a differential equation model, which is a common approach in infectious 
disease.  The model fit to 2000 through 2008 surveillance data for the US- and foreign-born 
populations.  The model allowed for external recruitment of people arriving in the US with LTBI 
and distinguished between recent infection, which includes people who developed disease 
within 2 years of infection, and long-term reactivated TB.  The model allowed for cross-infection 
between US-born and foreign-born populations.  Parameter ranges were drawn in accordance 
with current epidemiological literature.  DTBE staff ran many scenarios of the parameter values 
to assess the model. 
Dr. Hill presented to ACET a diagram of the model flow, which begins with US births and foreign 
arrivals into a mostly susceptible population.  The model assumes that the US births do not 
have TB and that the foreign-born arrivals are susceptible at a rate of approximately 80%.  By 
coming into contact with a person with infectious TB, there is a probability that a susceptible 
person can develop either acute latent infection, which progresses to disease quickly, or long-
term latent infection, labeled “Chronic LTBI,” which progresses to disease via reactivation.  The 
model distinguishes between infectious and non-infectious TB.  It also allows for re-infection, in 
which case a person infected with long-term, latent infection can be re-infected by coming into 
contact with an infectious person.  The route to active TB disease is then accelerated.  Because 
of mathematical limitations, it was not possible to model foreign-born persons who leave the US 
for their country of origin and then return to the US.  Further refinement of the model is needed 
to accommodate this scenario, which is likely to worsen the projections of incidence rates.  The 
model assumes that people with infectious or non-infectious TB are being treated at a high rate 
in the US and also allows for the treatment of latent infection.  The model can assess the impact 
of increasing treatment of latent infection on projected incidence rates as well as the impact of 
the proportion of arrivals of foreign-born persons with LTBI. 
The model yielded densities for best-fitting parameters for 2000 through 2008 incidence 
observations.  Over a range of different parameter fits, the density projects a median elimination 
year of 2063 among the US-born population.  The model supports a continuation of current 
trends of declines of 5.9% per year in the US-born population.  The situation is different among 
the foreign-born population.  The model indicates that TB elimination is generally not achievable 
for the foreign-born population.  The median range of TB incidence in the foreign-born 
population in the year 2100 is 119 cases per million.  According to this model, current trends in 
the foreign-born population are not likely to lead to TB elimination among the foreign-born 
population.  The overall incidence rate is projected to be 21 per million in the long-term. 
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The model considered scenarios with different TB interventions in the US- and foreign-born 
populations.  The baseline projection assumes no changes in treatment or screening and yields 
a median incidence rate of 100 to 150 cases per million in 2050 for the foreign-born population.  
Various scenarios were considered for the foreign-born population.  One scenario assumed 
instantaneous reduction of transmission so that all TB incidence results from reactivated TB.  
That scenario yields a median of approximately 100 cases per million in 2050.  The next 
scenario assumed persisting transmission, but doubled the treatment rate for LTBI.  This 
approach shows more promise, with a median rate of approximately 80 cases per million, but is 
still well above the elimination target of 1 case per million.  A scenario that both doubles the 
LTBI treatment rate and reduces by 50% the latent infection of people arriving in the US yields 
better results, with a median rate of approximately 50 cases per million.  Adding reduction of 
transmission to that scenario results in an even lower rate.  Dr. Hill emphasized that it is not 
possible to cut transmission instantly, but the model asks “what if” and assesses the likely 
impacts.  Even with a range of strategies, the model suggests that it will be difficult to achieve 
TB elimination in the foreign-born population. 
 
Dr. Hill presented graphic time-series curves of a range of incidence projections to 2060 from 
best-fit parameter sets that assume doubling the treatment of LTBI.  Even with doubling 
treatment, the range of incidence among the foreign-born population is reduced from 
approximately 150 cases per million to 100 cases per million.  The rates are still far above the 
elimination target.  Projections for the US-born population are more optimistic.  If LTBI treatment 
rates are doubled, then the elimination target could be achieved 20 years sooner than if no 
changes are made. 
 
A sensitivity analysis tested the results of the model projections and determined which 
parameters had the most effect on model projections of incidence.  The projected year of 
elimination for the US-born population is sensitive to the treatment rate of LTBI; the assumed 
level of contact between US-born and foreign-born populations; and the annual risk of infection.  
The projected long-term incidence in the foreign-born population is sensitive to the LTBI 
treatment rate; the reactivation progression rate among the foreign-born, which was calibrated 
separately from the US-born; and the level of importation of LTBI among new arrivals. 
 
If current TB control efforts are maintained, then elimination of TB among the US-born 
population can be expected by the end of the 21st century, perhaps as early as 2060.  
Elimination of TB among the foreign-born population is unlikely by 2100, even with higher rates 
of targeted testing and treatment of LTBI.  Cutting transmission as an interim step could hasten 
elimination among the US-born population, but foreign-born incidence rates would remain high. 
 
The results of this work were published online and in the Journal of Epidemiology and Infection, 
and Dr. Hill thanked his co-authors, Drs. J. E. Becerra and Ken Castro.  He acknowledged his 
other CDC colleagues who contributed to the effort. 
 
Discussion Points 
 
ACET thanked Dr. Hill for the presentation and agreed that the results of the modeling 
projections are sobering.  Nevertheless, they should remain optimistic in setting goals for TB 
elimination. 
 
ACET observed that increasing treatment of LTBI depends on a number of operational elements 
of TB control, which are understandable to people who work “on the front lines” of TB control.  
These elements include the speed or delay of contact investigations; the thoroughness of 
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contact investigations; the proportion of infected people who start isoniazid and the proportion 
who complete treatment with isoniazid; and efficacy.  Including these elements in the model 
would help front-line personnel understand why it is important to do what they are doing. 
 
Dr. Hill agreed and hoped that those elements of LTBI treatment could be included in a Web-
based, interactive model utilizing a different model paradigm that will allow for new parameters 
to be introduced.  The differential equation model is commonly used in infectious disease 
models, but it has a “sledgehammer approach” in that it assumes constant parameters.  He said 
that the software used for the modeling is called “R.”  It has differential equation capability as 
well as the capability to take into account a range of densities and projections.   
 
ACET requested a link to the paper published in the Journal of Epidemiology and Infection, or a 
copy of the paper.  Dr. Hill indicated that he would provide that information. 
 
There was discussion among ACET regarding how to apply the results of this modeling to 
policy, perhaps by encouraging public health programs to place more emphasis on LTBI in light 
of limited resources, or whether other areas of focus will have more impact.  CDC or ACET 
could utilize the model projections to create practical recommendations for public health. 
 
One of the assumptions in the model was an immediate cutoff of transmission.  Given 
decreased resources and the scale-back of services for TB control at the state level, diagnoses 
of TB are made later and later.  Further, TB control personnel are seeing pediatric TB, which is 
a marker of community transmission.  ACET asked how a longer duration of infectiousness 
might change the model, given that the period of transmission in communities is prolonged. 
 
Dr. Hill replied that the direct effect of increasing the duration of infectiousness will be an 
increase in the number of secondary cases arising from a single-source case.  Incidence rates 
will increase, and the declines in incidence rates will slow down.  This effect is generally true for 
all infectious disease models. 
 
ACET cautioned that the estimates of new MDR-TB cases in almost every country are likely to 
be underestimated. 
 
The term “re-activation” may mean different things to different people, and ACET inquired about 
the most common causes of reactivation of LTBI in the US and whether the cause might be re-
infection, a result of individuals becoming immunocompromised, or as a result of the natural 
aging of the population. 
 
Dr. Hill replied that the chief cause of reactivation is likely to be aging of the population.  This 
model cannot address that question directly.  There are different progression rates for 
reactivated TB in different age groups.  According to the model, re-infection is “at the bottom of 
the list.” 
 
ACET expressed concern regarding the rapidly increasing number of patients, particularly those 
with arthritis, who are being treated with immunocompromising drugs that are known to increase 
re-activation of TB.  ACET hoped that this phenomenon is being tracked so that the field may 
learn about its impact on the larger community and about how efficiently and rapidly TB is 
diagnosed in these patients. 
 
  
ACET Meeting Minutes                                               June 5, 2012 Page 8 
 
In response to a question from ACET regarding the effect of interaction between the foreign-
born and US-born populations on the model, Dr. Hill said that early versions of the model 
assumed no interaction between the two populations.  This approach is not realistic.  Cross-
contact was added to the model with the assumption of preferential mixing; that is, most 
contacts occurred within the foreign-born populations and the US-born populations.  The model 
allowed for random mixing in the background and assumed a certain amount of preferential 
mixing.  In the absence of good data about mixing, the researchers employed a model-fitting 
process, allowing the numbers to vary. 
 
Dr. Edward A. Nardell, a liaison representative to ACET from the International Union Against TB 
and Lung Disease, commented that the mathematical model approach to TB had been 
important to the field for some time and that Dr. Hill’s approach was refined and very good.  He 
noted the importance of re-infection among the foreign-born returning to their countries of origin.  
Re-infection plays a large role in the active TB disease process in high-burden countries and 
has an impact on the prospects of LTBI and vaccination.  US-born populations are then 
exposed as well.  Additionally, he asked about a scenario in which the infection to which these 
populations are exposed is increasingly multi-drug resistant or drug resistant.  This scenario is 
likely to occur internationally, as treatment for multi-drug resistant TB (MDR-TB) is not well-
handled.  He predicted that the impact of MDR-TB will be “bad.” 
 
Dr. Hill replied that they are considering other modeling paradigms, such as an individual-based 
model, which will allow for more flexibility than the differential equation models and should allow 
for the incorporation of persons who leave the US, become re-infected, and then return to the 
US.  He and his colleagues conducted an exercise to examine the effect that MDR-TB might 
have on incidence rates in the US.  The results appear in the online supplement to their paper in 
the Journal of Epidemiology and Infection.  If MDR-TB increases in the US as in other countries, 
the elimination projections will be worse.  In the sensitivity tests for MDR-TB, they assumed that 
MDR-TB in the foreign-born population increased from 1.2% of new cases, as reported in 2008, 
to 20% of new cases by the end of the 21st Century.  They assumed that the MDR-TB rates 
remained constant at the 2008 level for the US-born population.  Their exercise allowed for a 
reduction in the effectiveness of treatment of TB due to MDR-TB.  The resulting densities did 
not differ significantly for the US-born population, but the long-term incidence levels in the year 
2100 were worse in the foreign-born population.  Their modeling initially operated under 
optimistic assumptions by excluding MDR-TB and not modeling re-infection from the country of 
origin.  Even under these optimistic assumptions, the conclusions are pessimistic. 
 
Dr. Charles E. Wallace, an ACET liaison representative from the National Tuberculosis 
Controllers Association (NCTA), asked about the potential impact of shorter treatment regimens 
or the development of a vaccine. 
 
Dr. Hill answered that shorter treatment regimens and/or a vaccine would have an impact on the 
model.  He referred to models published by Dr. Christopher Dye and others in WHO.  CDC’s 
model is based on a publication by Dr. Dye that focused on global incidence levels outside sub-
Saharan Africa and that considered the impact of a vaccine.  In terms of the model, the 
development of a vaccine would remove individuals from a susceptible state to a recovered 
state.  Dr. Dye’s model indicated that combinations of vaccination of susceptible people and 
treatment of LTBI had a synergizing effect in addressing incidence rates.  Separately, the two 
approaches did not have as strong of an effect as the combination of the two.  If vaccines 
become available, then the projections will improve. 
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Dr. Andrew Vernon, DTBE, NCHHSTP, CDC, commented that several recent estimates suggest 
that the progression of LTBI is slower than the 5% to 10% estimate that has been used for some 
time.  He wondered how a change in the estimated progression of LTBI could affect the 
outcome of the model.  Further, he asked how curtailment of transmission in Mexico could 
influence the model. 
Dr. Hill responded that modeling the progression rate of LTBI is a challenge.  He recalled a 
detailed examination of LTBI progression in the US that was published approximately 15 years 
ago.  That research noted that progression is age-specific, but did not take into account the time 
since infection.  Thus far, models do not easily allow for the incorporation of how long a person 
has been infected or for assessing the likelihood of progression based on the time of infection.  
This issue needs to be addressed, and an individual-based model could incorporate the issue. 
Dr. Hill said that curtailing transmission in Mexico would likely have a considerable impact on 
the model and improve projections. 
Roll Call 
At 12:32 p.m. EDT, Dr. Hazel Dean called roll of ACET members, ex officio members, and 
liaison representatives.  She established a quorum for the meeting to continue. 
TB Outbreaks in Special Populations 
Thomas R. Navin, MD 
Chief, Surveillance, Epidemiology, Outbreak Investigation Branch 
Division of TB Elimination / NCHHSTP 
Centers for Disease Control and Prevention 
Dr. Navin reported to ACET progress on CDC’s work to predict TB disease outbreaks, which 
emphasizes the importance of special populations. 
Previously, Dr. Navin presented to ACET CDC’s work on running their prediction models against 
TB outbreaks which CDC had been involved in investigating.  The former presentation 
described the use of SaTScan and the county-based log likelihood ratio as well as CUSUM 
approaches to predicting outbreaks.  This work showed that 8 of 10 of the outbreaks could have 
been predicted, sometimes before the local program identified the outbreak, using these 
methods.  The next steps in this work focus on predicting TB outbreaks when they are still small 
clusters, utilizing routinely-collected surveillance data from CDC to predict future outbreaks. 
Dr. Navin explained that SaTScan is a freeware program used to detect spatial disease clusters.  
The program requires that the user input the geographic unit.  CDC collects Zip codes of 
collected TB cases with the TB genotype of interest as well as the Zip code of all other TB 
cases as comparison.  SaTScan also requires a search radius.  CDC has found that a search 
radius of 50 kilometers works well, although it will not capture all cases in an outbreak.  
SaTScan outputs include the Zip codes involved in the TB genotype cluster that is detected; the 
TB cases in the cluster; and the log-likelihood ratio and p value of the cluster. 
The analytic cohort for the study was clusters identified by SaTScan during the period 2006 
through 2010.  The study included significant as well as non-significant SaTScan clusters, and 
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the analysis used significance as a potential predictor.  This approach ensured that the study 
was not limited to significant clusters.  The analysis was restricted to clusters with at least 3 TB 
cases with the same genotype.  It will eventually be important to determine whether outbreaks 
can be predicted when only 2 cases are identified, but at this stage of the research, the 2-case 
model was somewhat unstable.  Further, it would be difficult to generate guidelines for TB 
controllers to investigate a TB cluster with a size of 2.  Significant resources are required to 
conduct a full outbreak investigation, and only a small portion of 2-case clusters grow.  When a 
third case is identified, however, a full outbreak investigation may be warranted. 
 
The study also limited findings to counties where genotyping coverage was at least 75%.  This 
limitation was placed on the study because the timeframe began in 2006, when many states 
had not yet started genotyping.  When a state starts genotyping, new clusters are identified, but 
it is not possible to determine whether the clusters are actually new, or whether they appear to 
be new because the state has just begun genotyping.  Further, the study focused on incident 
clusters that were just beginning so that the first 3 cases of the cluster could be defined.  
Therefore, the researchers eliminated clusters that had had cases in the previous 24 months. 
 
The observation period began on January 1, 2006, and ended on December 31, 2010.  An 
“outbreak” was defined as clusters that grew from 3 cases to 6 or more cases within 24 months 
of the third case.  Additionally, the outbreaks were confirmed by local TB controllers. 
 
SaTScan identified 3375 genotype clusters during the observation period.  Almost half of those 
clusters were located in counties that did not meet the inclusion criteria of at least 75% 
genotype coverage and were eliminated.  Of the 1513 that remained, 586 clusters were 
eliminated because their initial case was not preceded by a 24-month period of no reported 
cases of that genotype.  A total of 927 incident clusters with at least 2 cases remained.  Of 
those, 659 clusters were eliminated because they did not grow beyond 2 cases during the 
observation period.  Because of insufficient follow-up time, 120 of the 268 remaining clusters 
were eliminated.  The observation period for an outbreak, defined as the period between 
discovery of the third case and the next case, was 24 months.  The standard follow-up time was 
24 months, and it was sufficient to identify clusters that became outbreaks.  Ultimately, 148 
clusters sized 3 or more with 24 months of follow-up were identified, and 146 of them were 
included in the study cohort, as the outcomes of 2 clusters were not identified. 
 
Dr. Navin shared the study’s remarkable finding that many clusters do not grow beyond 2 cases.  
In the past, examinations of recent transmission made no distinction between clusters of size 2 
and clusters of size 20: all clusters are considered to be recent transmission.  This study 
showed, however, a dramatic difference in the sizes of clusters.  Next, Dr. Navin showed the 
data of clusters sized 6 or greater stratified by which cases were identified as outbreaks by local 
TB controllers.  As clusters grow in size, the size definition is a better predictor of an outbreak. 
 
Of the final cohort of 146 clusters greater than 3, 72 did not grow during the observation period.  
Some growth was seen in 52 of the clusters, which grew to 4 or 5 cases.  Six clusters grew to 
six or greater, but were not confirmed to be outbreaks.  Finally, 16 clusters, 11% of the cohort, 
grew to 6 or more cases and were confirmed to be outbreaks. 
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The analysis of which clusters would become outbreaks yielded several predictors.  Numerous 
predictors were considered among the first 3 cases in the cluster, and the researchers 
determined that at least one of the first 3 cases should have one of the predictors, unless 
indicated otherwise.  The results of the study include a relative risk table and a decision tree 
analysis. 
 
The group of patient characteristics with the highest relative risk, 17.7, was a combination 
termed “marginalized.”  This characteristic includes homelessness, reported excess alcohol use, 
reported drug abuse, or incarceration at diagnosis.  The next-highest relative risk was a 
combination of homelessness or alcohol or drug use.  The third-highest relative risk was drug 
use alone; the fourth was alcohol use alone; the fifth was homelessness or alcohol use; the 
sixth was homelessness and alcohol use; the seventh was incarceration; and the eighth was 
homelessness.  These results emphasize the importance of the “marginalized” characteristics in 
predicting outbreaks. 
 
The relative risk of having a significant log-likelihood ratio at the third case was 3.5.  The time 
between the first to the third case was important as well.  If the time was less than 5.3 months, 
then the relative risk is 3.2.  The number of 5.3 months comes from a decision tree analysis and 
indicates the optimal cut point. 
 
The decision tree analysis was created by software called JMP, an SAS predictive modeling 
software.  The program uses recursive partitioning to systematically analyze binary partitions of 
the data to identify the one with the best discrimination, based on the analysis of the negative 
log of the p value.  Once a partition is made, the program moved to each of 2 subordinate data 
groups to identify the best partition.  JMP can handle continuous values by evaluating all 
possible cuts or groupings. 
 
The JMP analysis began with the cohort of 146 clusters, 11% of which were identified as 
outbreaks.  JMP determined that the best first split was whether at least 1 of the first 3 cluster 
cases was part of the marginalized group: 67 of the 146 clusters had that characteristic, and of 
those, 15, or 22.4%, became outbreaks.  The predictive value is not high, but in the 79 clusters 
in which none of the first 3 cases were from the marginalized group, only 1 became an 
outbreak. 
 
Of the 67 clusters with at least 1 case in the marginalized group, JMP selected rapid growth as 
the next cut point.  In 17 of the 67 clusters, the third patient in a cluster was identified less than 
5.3 months after the first case was identified.  Nine of those cases, or 52.9%, became 
outbreaks.  The remaining 50 clusters had third cases identified more than 5.3 months after the 
first case, and 6 of them, or 12%, became outbreaks. 
 
Dr. Navin divided the decision tree into 3 outcomes:  high risk, medium risk, and low risk.  The 
high risk group, which includes the 9 clusters that became outbreaks that included cases with 
marginalized characteristics and showed rapid growth, should be considered targets for 
intervention.  Intervening early in these clusters could result in half of the outbreaks being 
prevented.  The predictive value of this approach is 53%.  The specificity is 94%, and the 
algorithm is successful at identifying clusters that are at low risk for becoming outbreaks.  The 
sensitivity is 56%, indicating that the algorithm would miss a number of outbreaks.  However, 
the sensitivity ratio does a disservice to the approach, as it the algorithm is based on clusters 
sized three or greater.  If a cluster in the medium-risk group grew to 4 cases, then there would 
be an opportunity to intervene. 
ACET Meeting Minutes                                               June 5, 2012 Page 12 
 
The 24-month time period of follow-up after the third case was reasonable, based on data on 
the survival distribution function of all of the clusters in the study after they grew to 3 cases.  The 
data show transition to 6 cases or more, and the last transition occurred within 24 months.  After 
that time, none of the clusters grew to 6 or more cases. 
 
This approach has several limitations.  It is based on surveillance data, which is not collected for 
the purpose of doing these types of analyses.  However, this limitation could be perceived as a 
strength, because the data used in the algorithm is reported routinely to CDC.  As genotyping 
techniques improve and as the field transitions from MIRU-12 to MIRU-24, more data will be 
collected to refine and extend the analysis.  Another limitation of the approach is that the 
observation period was only 5 years, with a 2-year follow-up.  In coming years, they hope to 
repeat and extend the analysis over a longer period.  Additionally, the requirement of 75% 
genotyping coverage at the county level resulted in the elimination of over half of the clusters 
that were initially identified.  As of 2011, genotyping coverage is well over 90%, so future 
analyses will likely be able to eliminate that restriction.  Finally, the data for this analysis is 
based on MIRU-12, and in the coming years, data from the more specific MIRU-24 will be 
available. 
 
With this methodology, it is possible to identify high-risk clusters that have a 53% chance of 
becoming outbreaks.  This provides an approach to prioritizing clusters for early intervention.  
With that, Dr. Navin thanked his colleagues at DTBE. 
 
Discussion Points 
 
ACET commended Dr. Navin on the excellent presentation. 
 
ACET noted that in order to evaluate the analysis, it would be ideal to determine whether all 
information regarding the patients is available.  For instance, information about chronic disease, 
smear positivity, and HIV status would be helpful.  Additionally, laryngeal TB can be extremely 
transmissible. 
 
Dr. Navin answered that information about patients’ HIV status and smear status, as well as all 
of the data reported as part of the RVCT surveillance data set.  The traditional predictors of 
infectiousness, including cavitary disease and smear-positive disease, are also predictors of 
outbreak growth.  Interestingly, the decision tree analysis chose the social risk factors and time 
factors significantly before the traditional infectiousness categories.  The surveillance data may 
not capture those variables accurately, but it is also possible that there is a difference between 
infectiousness and rapid-growth outbreaks.  It is remarkable how many outbreak investigations 
focus on homeless shelters, jails, and other unstable populations.  Outbreaks include highly 
infectious source cases, but they also include a population with poor access to healthcare 
among persons who live in a confined environment and who experience delays in TB diagnosis. 
 
ACET asked whether this analysis would be possible without the follow-up cutoff of 24 months.  
Dr. Navin said that the easiest way to address this limitation will be to conduct more analysis to 
determine the influence of longer observation periods.  It is interesting that the data for this 
analysis indicate that outbreaks develop quickly. 
 
In response to a question from ACET, Dr. Navin said that the analysis considered US-born 
versus foreign-born populations in many different ways.  In general, having at least 1 of the first 
3 cases in the cluster be U.S. born was more predictive of an outbreak than when all cases 
were foreign-born.  Many outbreaks in the US and in this data set included mostly Hispanic 
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persons, although not all were foreign-born.  It is important to analyze more data to tease out 
differences between the two populations.  A foreign-born person can be infectious and can 
serve as the source case for an outbreak; however, in the US today, the large and rapidly 
growing outbreaks are often almost exclusively among the US-born. 
 
ACET commented that a few types of transmission mechanisms can cause TB outbreaks.  For 
instance, TB is highly infectious among the vulnerable populations of HIV-positive individuals, 
which can lead to multiple infectious cases and ongoing transmission.  Assessment of the 
environment is important in addition to understanding the characteristics of the patients. 
 
Dr. Navin agreed that such factors are important, but the model is limited because some of the 
factors are not captured by the RVCT surveillance data. 
 
Dr. Nardell asked about the role of the TB controllers’ opinion of whether an outbreak had 
occurred.  He also asked about recent observations regarding the variability of human 
transmission of TB, which reinforces the idea that smear positivity, coughing, and cavitation are 
not sufficient.  He agreed that the environment and the host play a role, as does the specific 
strain of TB.  Certain strains are associated with outbreaks, which presents an opportunity to 
combine the collection of “fingerprints” to determine the impact of the TB strain. 
 
Dr. Navin said that outbreaks were defined by a two-step, sequential process.  First, they used 
surveillance data to define clusters that grew to at least 6 cases.  Next, that information was 
sent to the pertinent TB controller, who was asked to review their data on the clusters and to 
report whether they were aware of the cluster; whether it had been investigated; and whether 
the cluster represented an outbreak, in their opinion.  The process included substantial back-
and-forth dialogue regarding the definition of what constitutes a TB outbreak and reiterated the 
difficulty in coming to consensus about a TB outbreak.  Further, the process emphasized the 
need to create a reasonable definition of a TB outbreak for surveillance purposes, which 
included confirmation by a local TB health official. The TB controllers invested time in 
considering the clusters.  Save in two cases, the controllers were able to state which clusters 
were outbreaks.  He acknowledged a risk for circularity.  For instance, if one of the clusters was 
not investigated and no epidemiologic links were made, then the cluster might have been an 
outbreak, but unknown.  Regarding strains, he said that one of the limitations of this approach to 
modeling is its inherent crudeness.  The decision tree was stopped after two decision points 
because of the low number of clusters available for analysis.  Every year, more data will be 
available, so it may be possible to address specific strains. 
 
Dr. Susan M. Ray, an ACET liaison representative from the Infectious Disease Society of 
America, asked about the model’s exclusion of genotypes that are known to be endemic.  
Excluding these genotypes may result in the model “missing” some important outbreaks that 
start in a population of people with a number of risk factors for TB and that spread within a 
community, becoming amplified in a short period of time. 
 
Dr. Navin answered that the researchers debated this point a great deal.  Their approach was 
logical because they wanted first to assess clusters in which they could be fairly certain that 
they were seeing the first few cases.  He had been surprised that even this approach indicated 
rapid growth as a predictor of an outbreak.  That finding of rapid growth, which does not require 
identifying the first case, can be used to search the surveillance data for any cluster with rapid 
growth between cases.  Sudden growth of endemic clusters will be important to identify and 
predict, he agreed, and could be a next step for the work. 
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Dr. Ray noted that the marginalized population identified in the model was highly likely to have 
been recently incarcerated, but this risk factor is not captured by the RBCT surveillance.  
Recent incarceration is a strong risk factor, and it is one of the main reasons for continued 
transmission.  Local health departments are aware of this factor and note which patients have 
been recently incarcerated.  She suggested including recent incarceration in the discussion. 
 
Dr. Vernon observed that censoring the follow-up period is likely to have an impact on what is 
observed and what is allowed to grow to a certain size.  As genotyping expands, he encouraged 
Dr. Navin to look beyond that data point.  By eliminating cases that have had the genotype in 
the prior 24 months, outbreaks are defined as events that have to occur within a set period of 
time.  TB works on a long timeframe, as it is a slow-growing infection that has a slow 
transmission time.  The definition of an outbreak could be “more than what is expected.”  In 
addition to the marginalized population as a risk factor, he noted that little is known about 
household size.  In effect, the marginalized populations have “very large households.”  If the 
analysis were stratified by household size, he predicted that small households would be unlikely 
to grow clusters, where households of 10 or more would be more likely to grow clusters. 
 
Dr. Navin agreed and added that they were eager to address these ideas as more data are 
gathered. 
TRUST – How to Manage Budget Cuts 
 
Tuberculosis Elimination in the United States: Future Directions and Challenges 
RADM Kenneth G. Castro, MD 
Director, Division of Tuberculosis Elimination / NCHHSTP 
Centers for Disease Control and Prevention 
 
Dr. Castro reminded ACET that the presentations they had heard would frame their discussion 
of thinking strategically about ACET’s focus in the coming years.  He presented ACET with an 
overview of DTBE’s missions, priorities, recent progress, funds, and anticipated funds and 
distribution. 
 
The mission statement of DTBE is “to promote health and quality of life by preventing, 
controlling, and eventually eliminating tuberculosis from the United States, and by collaborating 
with other countries and international partners in controlling global tuberculosis.”  In 1989, the 
definition of elimination was established as having no more than 1 case of TB disease per 
million population.  DTBE’s role is primarily domestic, but epidemiology from the Institute of 
Medicine (IOM) in 2000 reinforced the need to engage in the global fight against tuberculosis.  
Key partnerships for DTBE include state and local health departments and laboratories; NTCA 
and Stop TB USA; several professional organizations such as the Association of Public Health 
Laboratories (APHL), the American Thoracic Society (ATS), and others; the Federal TB Task 
Force; WHO; Stop TB Partnership; and Ministries of Health and National TB Programs. 
 
DTBE has articulated 5 priorities: 
 
 Prevent new cases of infection and disease with Mycobacterium tuberculosis and find 
and cure all persons with TB; 
 Reduce TB in foreign-born persons residing in, or traveling to, the US; 
 Reduce TB in US racial and ethnic minority populations and measure and address social 
determinants of health; 
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 Reduce the impact of MDR-TB and extensively drug-resistant (XDR) TB in the US and 
globally; and 
 Reduce HIV-associated TB in the US and globally. 
 
Following the resurgence in TB that occurred from 1985 through 1992, the TB trends have 
declined.  As of 2011, the case rate is 3.4 per 100,000, or 10,521 TB cases.  Most successful 
programs suffer the consequence of being perceived as less necessary: the annual CDC TB 
budget has dropped slightly, and is projected to drop in 2013, adjusting the dollars to the 1990 
Consumer Price Index (CPI) for Medical Care shows a 50% drop in purchasing power from 
1994 to the present. 
 
DTBE’s challenges include making the best use of these resources.  The largest portion of the 
TB budget supports program activities through cooperative agreements.  Dr. Castro explained 
to ACET DTBE’s plans, created with their partners’ input, for how best to utilize these resources.  
Approximately 10-13% of the TB budget is focused on research activities, including TB 
epidemiologic studies and the TB Trials Consortium (TBTC). 
 
The funding formula was changed in 2005.  Under the new formula, 20% of the cooperative 
agreement funds were redistributed based on a need-based formula.  This formula includes 
morbidity and “the complexity of cases,” such as whether the cases were HIV-infected, MDR-
TB, or in the foreign-born or recent arrivals.  After 3 years, DBTE increased the redistributed 
funds to 35%.  DTBE aims to redistribute 60% of the cooperative agreement funds based on the 
new formula in 2013.  Also in 2013, the formula will incorporate a performance-based 
component, which will incentivize completion of therapy and obtaining drug susceptibility test 
results for all culture-positive individuals.  In 2014, 80% of the resources will be distributed on 
the basis of the formula, and by 2015, DTBE plans for all cooperative agreements to be 
distributed exclusively on the basis of the needs-based and performance-based formula.  The 
current plans are to limit the performance-based component to 20% of the funds, but the 
division will determine over time if the approach needs to be adjusted.  This approach allows 
them to focus their limited resources on need and on performance.  DTBE has worked with its 
partners as well as with PGO to ensure that these changes can be made.  The Request for 
Applications (RFA) does not provide details of the funding formula, enabling DTBE to work 
within the spirit of the cooperative agreement to revise the formula as the epidemiology evolves 
over time. 
 
Ultimately, DTBE aims to sustain the commitment to eliminating TB by focusing on the core 
public health functions of prevention, control, evaluation, and laboratory support to state and 
local health departments.  The division will continue to provide preparedness and outbreak 
response and program-relevant research for new tools and efficiencies.  The division also 
ensures workforce expertise through training and education and expert medical consultation.  
Further, DTBE will continue to provide technical support for global response. 
 
Dr. Castro described several challenges that the division faces.  The proportion of 
disenfranchised persons with TB is growing.  The global burden and the proportion of foreign-
born persons with TB are also growing.  Sporadic outbreaks continue to occur, despite declining 
TB trends, most commonly due to drug-susceptible and drug-resistant TB.  Other challenges 
include evolving technologies and the perception of a lack of profit margin in the US, which limit 
potential applications for Food and Drug Administration (FDA) approval.  ACET has helped 
DTBE draw attention to the challenge of second-line drug shortages. 
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Dr. Castro presented questions for ACET to consider, with the presentations in mind: 
 Do you agree with the core public health functions identified by CDC? 
 What is missing? 
 What could be stopped? 
Discussion Points 
ACET commented on the additional challenge of the loss of experienced public health 
workforce, which is combined with a loss of expertise in the private sector community regarding 
recognition, diagnosis, care, and management of TB patients.  These challenges could factor 
into the prevention and control funding formula.  For instance, the loss of experienced public 
health workforce could support slowing the progression from the pre-formula distribution to the 
needs- and performance-based formula.  Alternatively, it may not be a good use of resources to 
train workforce in areas where they may never see a TB case. 
Dr. Castro responded that these concerns are captured as part of the core public health function 
of workforce expertise.  The work of the regional training and medical consultation centers is 
justified and could be a mechanism for focusing training efforts and not expecting the whole 
country to be proficient in TB management.  Providers should be expected to be mindful of TB, 
however, in a manner analogous to the expectation that a general practitioner would consider 
leukemia in a patient with anemia and other symptoms, and refer that patient appropriately.  The 
impact of delays in diagnosis is significant, resulting in transmission of the disease as well as 
advanced disease in the patient. 
ACET requested details regarding how the limited resources could be divided among the core 
public health functions, all of which are extremely important for TB control in the US.  Dr. Castro 
offered to obtain the allocations for ACET.  Most of the funds are devoted to prevention and 
control, evaluation, and laboratory support. 
The ACET working group that focuses on TB control has discussed focusing aggressive 
attention on intervening in high-risk clusters and on the extent of TB in the detainee and 
incarcerated populations.  New technologies for detection of latent infection, in particular, could 
have a rapid impact in these populations. 
Dr. Castro agreed that those populations require a high level of attention.  DTBE will continue to 
refine the modeling structure to determine the relative value of interventions. 
Regarding the challenge of evolving technologies and the perception of lack of profit, Dr. Castro 
said that while the rest of the world has access to GeneXpert, it has not been FDA-approved for 
use in the US.  Globally, GeneXpert has been used to achieve TB diagnosis in the pediatric 
population.  Second-line drug shortages are another challenge.  For instance, no kanamycin is 
available in the US.  CDC will work with FDA in hopes of obtaining waivers for drugs that are 
manufactured elsewhere under good manufacturing practices. 
Regarding what is missing, ACET observed that many discussions of programs and systems 
focus on what the taxpayer wants.  It is assumed that the taxpayer does not want to be exposed 
to TB.  Activities tend to focus on active response, but TB prevention may need to be addressed 
and promoted more strongly, especially among high-risk populations. 
ACET Meeting Minutes                                               June 5, 2012 Page 17 
 
Dr. Castro agreed and noted that prevention is an important element of TB elimination.  The 
recent recommendations for a 12-dose regimen among contacts can be applied to readily 
accessible high-risk subpopulations, such as recent immigrants and refugees with a B1 or B2 
classification. 
ACET referred to the education of healthcare workers and to the example of a practitioner 
screening for leukemia.  Leukemia is considered to be a relatively rare diagnosis, but the 
incidence of leukemia in the US is approximately 12.5 per 100,000.  This incidence is 4 times 
the amount of active TB that is diagnosed.  Internists can diagnose leukemia with a routine test 
that detects a large variety of diseases.  TB presents an even rarer disease that requires a 
specific test. 
Dr. Castro agreed.  The Union and WHO worked with the Practical Approach to Lung Health 
(PAL) in a global setting.  This case-funding tool for a rare disease could be useful in the US as 
well and for evaluation of contacts.  He supported a focused approach to educating 
practitioners.  For instance, a person with HIV infection and other co-morbidities that have a 
high risk of being associated with TB should have a pre-test.  New diagnostics may play a role 
in this work.  In the future, polymerase chain reaction (PCR) technology could be relied upon for 
diagnosis of a variety of infectious pulmonary agents.  Adding TB to that approach would 
eliminate the need to order a new test.  He acknowledged that TB requires a good sputum 
specimen, but in an ideal scenario, a multiplex assay would be able to diagnose TB and other 
respiratory infections.  The PAL concept could be revisited in light of new technologies. 
ACET commented on the performance indicator of completion of treatment.  At the recent US-
México Border TB Consortium meeting, there was discussion regarding whether that 
requirement extends to a requirement to report completion of treatment, even for patients that 
have moved outside the US.  That requirement would place a responsibility on TB programs 
that they cannot control.  There are issues surrounding how completion of treatment information 
will be obtained.  TB programs in other countries may or may not be responsive, especially if 
they are being contacted by multiple entities in the US.  The requirement may place additional 
burdens on entities such as the Cure TB Program and TB Net that are not funded to fulfill the 
requirement.  Border states are particularly concerned about this issue, and a centralized 
approach to getting the information, perhaps through CDC, would be preferable. 
Dr. Castro replied that those details are being finalized.  He expected to see a concerted effort 
to collect information about completion therapy status for anyone who moves from one 
jurisdiction in the US to another.  The challenges are greater when a person moves outside the 
US; however, a systematic effort has not been made to reach out to national TB programs 
overseas.  He agreed that working with Cure TB or TB Net to collect information on people who 
go to Mexico would be beneficial.  A potential approach would include a per capita bonus when 
outcomes are defined reliably, but penalties would apply for not knowing therapy completion 
status.  He noted that he had received information from the Canada TB program, which he 
passes to the relevant jurisdiction.  He agreed that CDC should be a full partner in this 
enterprise. 
ACET recommended that the list of DTBE priorities, which includes racial and ethnic priorities, 
should also include the incarcerated population.  Primary care, emergency room personnel, and 
prison health personnel in communities often are not familiar with TB. 
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ACET wondered whether it is fair to use the CPI for inflationary characteristics, as opposed to 
using the Gross National Product (GNP) deflator.  Dr. Castro answered that the graph he 
provided is also available using the Biomedical Research and Development Price Index 
(BRDPI), which is what NIH traditionally uses.  The graphs are very similar, however. 
ACET asked about reducing funding to successful programs that may not demonstrate need.  
Dr. Castro answered that the performance-based aspects of the program are intended to 
address this issue.  Successful programs are likely to lose resources, but if they continue to 
perform well, then they will be able to retain federal resources. 
Dr. Nardell agreed that taking funds from successful programs may reinforce the U-shaped 
curve, but the performance-based aspect of the formula addresses this issue.  Additionally, he 
noted that the last case will be the most expensive to eliminate, and he wondered whether 
consideration had been given to the fact that as cases decrease, costs do not proportionally 
decrease. 
Dr. Castro replied that no less than $100,000 will be provided to jurisdictions to ensure that at 
least one person is hired to conduct TB surveillance and some aspect of TB control.  He agreed 
that as time goes on, the interventions are not cost-effective.  The TB community needs to 
better make the argument that responding to a disaster costs more than if the original 
investment had been maintained.  CDC Director Dr. Frieden and others wrote a paper in The 
New England Journal of Medicine in the 1990s to this effect, titled “Turning the Tide.”  A $1 
billion investment was required order to recover from resurgent TB in New York alone. 
ACET asked about the implications that Program Collaboration Service Integration (PCSI) has 
had for TB programs at local levels, and any expected implications for the future.  Dr. Castro 
answered that the implications of PCSI remain to be seen.  He expected that in very low-
morbidity areas, PCSI is likely to secure some level of infrastructure where some individuals in 
public health departments are cross-trained in necessary functions, such as TB contact 
investigations as well as STD case tracing.  In the discussions regarding the Affordable Care 
Act (ACA), he has been impressed to hear that policymakers understand that TB control is 
different from other health concerns, and expansion of health insurance coverage is not likely to 
be the solution for TB, particularly given the nature of the populations affected by TB. 
Given the current fiscal austerity at most state and local health departments, ACET asked about 
the likelihood that TB will become even less of a priority there.  Dr. Castro replied that TB is 
already of relatively low priority at most health departments.  
ACET commented on the NHAS and the Viral Hepatitis Plan and asked whether the 
administration has lost track of TB and the TB Elimination plan.  Dr. Castro felt that TB had been 
lost and said that ACET could play a role in rectifying the situation.  Mr. Jones, ACET Chair, 
recently met with Dr. Howard Koh.  That meeting offered opportunities for follow-up.  ACET can 
pursue a report outlining needs regarding TB and a clear “ask” of HHS. 
Dr. Wallace commented on the lack of a strong, committed approach to controlling TB in the 10 
US states that border México.  He emphasized the need for action and a global response 
focused on México as opposed to other countries.  The state of Texas makes a heavy 
investment in bi-national, second-line drug projects.  CDC’s focus on TB in the African American 
population has decreased, and he suggested increasing focus on this population that continues 
to get TB.  Immediate action is needed in this area. 
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It was clarified that the funding for TB prevention and control in different countries comes from 
different funding streams. 
 
With that, Mr. Jones closed the discussion and dismissed the group for a break at 2:11 pm.  The 
meeting resumed at 2:33 pm.  Dr. Dean called roll and established a quorum. 
Developing a 3 – 5 Year Strategic Plan for ACET 
 
Shannon Jones III 
Acting Director of Public Health and Community Services, 
City of Austin / Travis County 
Texas Health and Human Services Department 
ACET Chair 
 
Mr. Jones explained that the next session would focus on ACET’s efforts to assess where the 
committee stands and how the committee can support DTBE.  He observed ebb and flow over 
the years in ACET’s efforts to communicate with HHS and the CDC administration.  He asked 
ACET members, ex officio members, and liaison representatives to reflect on ACET’s priority 
initiatives.  ACET’s biannual report will be presented to the Secretary of HHS at the end of June 
2012.  That report will include ACET’s resolutions and recommendations and their statuses.  
The report will also touch on “big picture” goals for ACET’s future.  Mr. Jones added that 
comments would be welcome via email. 
 
ACET’s observations included the following: 
 
• TB prevention and control is a “victim of its own success,” as incidence rates have 
reduced for 18 years to 3 cases per 100,000.  TB could “drop out of sight” in budgets as 
well as in the perception of colleagues in the medical and public health worlds. 
• New Commissioners of Health or Public Health Directors may not have a sense of the 
history of TB, or of what may happen in the future with TB or MDR-TB if certain 
capabilities are not maintained. 
• Every message from ACET to the Secretary of HHS and to the administration at CDC 
should drive home the point that TB elimination and further control will be difficult with 
current resources, and future cuts will jeopardize the enterprise.  To paraphrase Dr. 
Castro, “You can pay now, or you can pay more later.” 
• CDC should be clearly involved in issues of drug supply, possibly serving as a central 
housing source for ensuring adequate supplies of TB drugs in the US. 
• CDC can contribute to the education of human resources in TB prevention and control 
within the US. 
• Scientific priorities in TB include shorter regimens and new drugs. 
• ACET can evaluate the impact that changes in healthcare in the US, including cuts in 
funding to public health, is impacting and will impact TB control. 
• The foreign-born population is important, and working with high-incidence countries is an 
important part of that effort. 
• ACET should help DTBE determine how best to utilize reduced funds.  ACET can help 
communicate challenges, but a main duty is this prioritization to reduce TB in the US. 
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• It will be challenging to eliminate TB in next few decades.  As ACET’s charter is to 
advise CDC and the CDC Director, the committee should support additional resources 
for TB control and elimination; however, given the reality of the current economy, ACET 
should also discuss priorities. 
• In the face of dwindling resources, it will be important for ACET to create approaches 
that allow for the ensuring of appropriate medical management of TB cases and LTBI so 
that they do not become drug-resistant TB cases.  This work involves working with 
access to second-line drugs, access to first-line drugs, and working through the ACA to 
ensure that TB services are appropriately and adequately covered.  An intervention is 
needed when the private sector is mismanaging a TB case, especially a drug-resistant 
TB case.  This work includes medication, toxicity monitoring, infection control, isolation, 
returning to work, and more. 
• The TB Elimination Plan is archaic compared to national plans for HIV and viral hepatitis.  
The TB plan needs outsiders’ points of view that can provide perspectives from local, 
state, and international public health interests.  The viral hepatitis strategy brought that 
disease to “center stage,” and TB needs a similar effort, which begins with “reinventing 
ourselves.” 
• While the case rate of TB in the US is relatively low, most people in the US are probably 
unaware that TB still exists, and that it is a deadly disease.  ACET can address issues of 
global funding and its impact on foreign-born cases in the US and the need for new 
drugs and new regimens. 
• ACET should take advantage of the successful meeting with Dr. Koh and of his interest 
in learning more.  Dr. Koh was instrumental in the viral hepatitis strategy and is also 
involved in a task force on adult immunizations as well as efforts concerning seasonal 
flu.  His support for the TB issue could be very important.  Perhaps he could address 
ACET, or another meeting could be arranged with him and ACET to talk about TB issues 
and next steps. 
• People may be confused because TB rates are declining, but the disparity issues in TB 
are still serious.  The disparity issues in TB parallel disparity issues in other diseases 
that are linked to TB, such as HIV, hepatitis C, and others.  The field does not have a 
good understanding of how many diabetics have latent infection. 
• ACET should consider new partners, such as the Centers for Medicare and Medicaid 
Services (CMS) and the Innovation Center, which focuses on ways to decrease adverse 
health outcomes for a number of different diseases. 
Dr. Nardell observed tension regarding resources that are devoted to global TB control versus 
domestic TB control.  Most domestic TB cases are in the foreign-born, and the global TB 
epidemic is raging.  A unified view is needed so that domestic efforts are viewed as a necessary 
part of a global epidemic.  The US is vulnerable to increasing rates of drug-resistant TB. 
Dr. Lornel Tompkins, an ACET liaison representative from the National Medical Association 
(NMA), appreciated the concept of including the local perspective as part of a global approach 
to TB.  She related her experience with active TB in a small community, in which the emergency 
room personnel reacted quickly to place the cases in isolation.  Because fewer cases are seen, 
healthcare personnel do not know how to diagnose TB, or do not think to diagnose TB.  The 
populations that are most at risk for TB, including immunosuppressed patients, can be missed 
because of a concentration on the foreign-born.  An inclusive approach is needed. 
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Dr. Wallace encouraged ACET to develop “a voice.”  ACET should support CDC in the battle for 
funding, helping to reach out to groups that can advocate for them.  A Senate Appropriations 
Committee will vote on TB funding on June 12, 2012, and it is important to help legislators 
understand the importance of TB funding.  Any cut to DTBE is a cut to the states, and many 
states cannot absorb these cuts. 
Mr. Jones asked ACET members, ex officio members, and liaison representatives to forward 
additional comments via email no later than June 15, 2012.  The ideas will be incorporated in 
the report to the Secretary of HHS. 
Mr. Jones suggested charging one of ACET’s working groups with examining the major points 
raised in the discussion and presenting ACET with coordinated action steps for the future.  The 
major areas suggested for ACET include: 
 Educating the HHS Secretary and CDC Administration 
 Making recommendations regarding funding priorities 
 Collaborating on domestic and global TB efforts 
 Addressing drug shortages, working with the private sector in specific ways 
 Engaging and addressing disparity issues 
It will be important for the group to suggest a specific “hook” and a specific “ask” to bring 
attention to the priority areas within TB. 
ACET suggested building substantive time into the ACET meeting to engage in dialogue 
regarding priorities and action steps to define ACET. 
Dr. Castro appreciated the priority areas that ACET had identified and particularly appreciated 
the need to continue to educate leadership within HHS. 
Business Section 
Shannon Jones III 
Acting Director of Public Health and Community Services, 
City of Austin / Travis County 
Texas Health and Human Services Department 
Topic 1 
A motion was properly placed on the floor by Dr. Masahiro Narita and seconded by Dr. Jane 
Carter to approve the minutes from the March 6 – 7, 2012 ACET meeting in Atlanta, Georgia.  
ACET unanimously approved the motion. 
Topic 2 
Mr. Jones asked ACET to discuss potential topics for the next ACET meeting and asked the 
chairs of the ACET Work Groups to indicate whether they would present updates. 
Dr. Cassell said that the TB Control Work Group has engaged in productive discussions with 
individuals within and outside the TB field.  A subgroup of the Work Group has met via 
conference call to examine specific opportunities to focus on Texas to identify best approaches 
to TB control.  The group will provide an update at the next ACET meeting. 
ACET Meeting Minutes                                               June 5, 2012 Page 22 
 
Dr. Carter said that the Corrections Work Group would provide a report at the next ACET 
meeting. 
At the next meeting, ACET will discuss whether the work of the Affordable Care Act Work Group 
and the Second-Line Drug Work Group has been accomplished and whether the Work Groups 
will be continued.  If so, then ACET will discuss their focus and structure, including identifying 
ACET members and liaison members who participate on the group.  In the meantime, the Work 
Groups will hold conference calls regarding their ideas for the future of the groups. 
Topic 3 
Regarding the bacille Calmette-Guerin (BCG) vaccine document, Dr. Dean clarified that ACET 
and the BCG Work Group have two options: 1) to publish the document as an ACET document, 
which would not go through CDC clearance; or 2) to turn the document over to CDC for 
publication, which would require CDC clearance.  Dr. Castro added a third option, to format and 
post the document on the DTBE webpage as ACET recommendations.  The document includes 
a summary of the literature and expert recommendations, on which ACET and CDC 
collaborated. 
In view of the time that has gone by, ACET determined that with some updating, the document 
should be reclaimed by ACET and published in a journal.  CDC personnel who contributed to 
the document can be acknowledged as subject matter experts, but the voice of ACET prevails in 
the document. 
Dr. Dean called roll to re-establish a quorum.  A quorum was present, so the meeting continued. 
A motion was properly placed on the floor by Dr. Jane Carter and seconded by Dr. Masahiro 
Narita to empower the BCG Document Work Group to choose to pursue publication of the BCG 
document as an ACET product.  Additionally, the BCG Document Work Group is empowered to 
pursue posting the BCG document on the DTBE website as a product of ACET.  ACET 
unanimously approved the motion. 
Topic 4 
ACET members, ex officio members, and liaison representatives will be sent a summary of all of 
the resolutions and recommendations that have been approved by ACET over the last 2 – 3 
years.  ACET is asked to make comments on the recommendations, and those comments will 
be included in the biannual ACET report to the HHS Secretary.  Feedback from ACET should be 
sent no later than June 15, 2012.  The report will be distributed to ACET members, ex officio 
members, and liaison representatives and will be public information. 
Topic 5 
The following ACET members volunteered to participate on the DTBE Health Equity Work 
Group: Dr. Masahiro Narita and Mr. Shannon Jones.  Dr. Warren Hewitt, ACET ex officio 
member, also volunteered to participate. 
Public Comment 
Mr. Jones opened the floor for public comment at 3:36 p.m. EDT.  Hearing none, the meeting 
proceeded. 
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Roll Call 
Dr. Dean conducted a roll call and established a quorum. 
Meeting Adjourned 
Dr. Castro noted that conducting the ACET meeting via teleconference as opposed to in person 
saved approximately $28,000.  He thanked the participants for their time and said that he would 
pursue a brief survey of meeting participants to inform future use of the format. 
Mr. Jones noted that the next ACET meeting is scheduled for December 4 – 5, 2012. 
With that, the meeting adjourned at 3:39 pm. 
Certification 
 
I hereby certify that, to the best of my knowledge and ability, the foregoing minutes of the June 
5, 2012, meeting of the Advisory Committee for the Elimination of Tuberculosis, CDC are 
accurate and complete. 
___________________   ________________________________ 
          Date     Shannon Jones III 
      Chair, Advisory Committee for the 
      Elimination of Tuberculosis, CDC 
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Attachment #1:  Attendance 
 
Note: Dr. Hazel Dean, ACET Designated Federal Official, conducted five roll calls on June 5, 
2012.  She verified the presence of a quorum of ACET voting members and ex officio members 
sufficient for ACET to conduct its business throughout the course of the teleconference. 
 
ACET Members 
Mr. Shannon Jones III, Chair 
Dr. Iram Bakhtawar 
Dr. Eric Brenner 
Dr. Marcos Burgos 
Dr. Jane Carter 
Dr. Gail Cassell 
Dr. Christine Hahn 
Dr. Masahiro Narita 
Dr. Barbara Seaworth 
 
ACET Designated Federal Official 
Dr. Hazel Dean, NCHHSTP Deputy Director 
 
ACET ex officio Members 
Dr. Naomi Aronson (Department of Defense) 
Dr. William B. Baine (Agency for Healthcare Research and Quality) 
Dr. Amy S. Bloom (US Agency for International Development) 
Ms. Sarah Bur (Federal Bureau of Prisons) 
Ms. Nadine J. Garcia (Office of Minority Health) 
Dr. Warren W. Hewitt, Jr. (Substance Abuse and Mental Health Administration) 
Dr. Mamodikoe Makhene (National Institute of Allergy and Infectious Diseases) 
Ms. Tiffany Moore (US Marshals Service) 
Dr. Sheldon Morris (Food and Drug Administration) 
Dr. Thomas Nerad (for Caroline Freeman, Occupational Safety and Health Administration) 
Dr. Gary Roselle (Department of Veterans Affairs) 
Dr. Diana Schneider (US Immigration and Customs Enforcement) 
Dr. Theresa Watkins-Bryant (Health Resources and Services Administration) 
 
ACET Liaison Representatives 
Dr. Frances P. Downes (Association of Public Health Laboratories) 
Ms. Cornelia Jervis (Treatment Action Group) 
Dr. Edward A. Nardell (International Union Against TB and Lung Disease) 
Dr. Susan M. Ray (Infectious Disease Society of America) 
Dr. Lornel Tompkins (National Medical Association) 
Dr. Charles E. Wallace (National Tuberculosis Controllers Association) (via telephone) 
 
CDC Representatives 
Dr. Kenneth Castro, Director, Division of Tuberculosis Elimination, NCHHSTP 
Dr. Suzanne Beavers 
Dr. Jose Becerra 
Dr. Sapna Bamrah 
Dr. Terence Chorba 
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Dr. John Douglas 
Ms. Teresa Durden 
Ms. Maria Fraire 
Ms. Demetria Gardner 
Dr. Denise Garrett 
Ms. Smita Ghosh 
Mr. Andrew Heetderks 
Dr. Andrew Hill 
Dr. Awal Khan 
Ms. Ann Lanner 
Dr. Robert Luo 
Dr. Suzanne Marks 
Dr. Thomas Navin 
Ms. Bonnie Plikaytis 
Dr. Krista Powell 
Mr. Robert Scott 
Ms. Margie Scott-Cseh 
Mr. Philip Talboy 
Dr. Andrew Vernon 
Dr. Wanda Walton 
Ms. Kai Young 
 
Members of the Public 
Ms. Kendra Cox (Cambridge Communications) 
Mr. John Seggerson (Stop TB USA) 
Ms. Elizabeth Stoller 
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Attachment #2:  Acronyms Used in This Document 
Acronym Expansion 
  
ACA Affordable Care Act 
ACET Advisory Council for the Elimination of Tuberculosis 
APHL Association of Public Health Laboratories 
ATS American Thoracic Society 
BCG Bacille Calmette-Guerin (vaccination) 
BRDPI Biomedical Research and Development Price Index 
CDC Centers for Disease Control and Prevention 
CMO Committee Management Office 
CMS Centers for Medicare and Medicaid Services 
CPI Consumer Price Index 
DTBE Division of Tuberculosis Elimination 
FDA Food and Drug Administration 
HHS (Department of) Health and Human Services 
HIV Human Immunodeficiency Virus 
IOM Institute of Medicine 
LTBI Latent Tuberculosis Infection 
MDR-TB Multidrug-Resistant Tuberculosis 
NEJM New England Journal of Medicine 
NHANES National Health and Nutrition Examination Survey 
NHAS National HIV/AIDS Strategy 
NIH National Institutes of Health 
NMA National Medical Association 
NTCA National Tuberculosis Controllers Association 
OGA Office of Global Affairs 
OMH Office of Minority Health 
PAL Practical Approach to Lung Health 
PCR Polymerase Chain Reaction 
PCSI Program Collaboration Service Integration 
PEPFAR President’s Emergency Plan for AIDS Relief 
PGO Procurement and Grants Office 
RFA Request for Applications 
RVCT  Report Verified Case of TB 
STD Sexually Transmitted Disease 
TB Tuberculosis 
TBTC Tuberculosis Trials Consortium 
US United States 
WHO World Health Organization 
XDR-TB Extensively Drug-Resistant Tuberculosis 
